Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy

Hepatitis B virus (HBV) reactivation occasionally occurs long after immunosuppressive therapy. The characteristics of late HBV reactivation remain unclear. We herein present a case of HBV reactivation in a patient with nonalcoholic steatohepatitis (NASH) more than 3 years after rituximab-containing...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 58; no. 3; pp. 375 - 380
Main Authors Hayashi, Manabu, Abe, Kazumichi, Fujita, Masashi, Okai, Ken, Takahashi, Atsushi, Ohira, Hiromasa
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society of Internal Medicine 01.02.2019
Japan Science and Technology Agency
Subjects
Activation
B-cell lymphoma
Case Report
Chemotherapy
Hepatitis
Hepatitis B
hepatitis B virus
Immunomodulation
Immunosuppressive agents
Internal medicine
Lymphocytes B
Lymphoma
Monoclonal antibodies
nonalcoholic steatohepatitis
reactivation
Rituximab
Statins
Targeted cancer therapy
Transaminase
Viruses
nonalcoholic steatohepatitis
reactivation
hepatitis B virus
rituximab
Online AccessGet full text

Cover

More Information
Summary:Hepatitis B virus (HBV) reactivation occasionally occurs long after immunosuppressive therapy. The characteristics of late HBV reactivation remain unclear. We herein present a case of HBV reactivation in a patient with nonalcoholic steatohepatitis (NASH) more than 3 years after rituximab-containing chemotherapy for diffuse large B-cell lymphoma. Increased transaminase levels, which were induced by NASH, were observed after chemotherapy and were alleviated with statin treatment. HBV reactivation was identified incidentally. The patient developed hepatitis that improved with entecavir therapy. Our case might indicate that the presence of NASH is associated with HBV reactivation long after treatment and that statins, as immune-modulatory agents, affect HBV reactivation.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Correspondence to Dr.　Manabu Hayashi, m884884@fmu.ac.jp
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.1587-18